Select Language
TSLP
TSLP Overview
| English Name | Thymic stromal lymphopoietin | Approved Drugs | 1 |
| Drugs in Clinical Trials | 28 | Target Synonym | Thymic stromal lymphopoietin，TSLP |
| Highest Development Stage | Approved | ||
| English Name | Thymic stromal lymphopoietin |
| Target Synonym | Thymic stromal lymphopoietin，TSLP |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 28 |
| Highest Development Stage | Approved |
TSLP Product List
- Product Category
Protein (17)Kits (2)
- Product Status
Launched (19)
- Species
Human (13)Mouse (2)Cynomolgus (3)Rat (1)
- Tag
His Tag & Avi Tag (4)His Tag (8)Mouse IgG Fc Tag (1)- (2)Fc Tag (2)Fc Tag & Avi Tag (2)
- Conjugate
Biotin-labeled (6)Unconjugated (10)- (2)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT TSP-H5243 |  Human | HEK293 | Human TSLP Protein (R127A, R130A), His Tag, low endotoxin (MALS verified) |  |  |  |
HOT TSP-H52Hb | Human | HEK293 | Human TSLP Protein, His Tag, premium grade |  | | |
HOT TSP-H82Eb | Human | HEK293 | Biotinylated Human TSLP Protein, His,Avitag™ (MALS verified) |  | | |
HOT TSP-M52H8 |  Mouse | HEK293 | Mouse TSLP Protein, His Tag (MALS verified) |  | | |
HOT TSP-C52H4 |  Cynomolgus | HEK293 | Cynomolgus TSLP (R127A, R130S) Protein, His Tag, low endotoxin (HPLC verified) |  | | |
HOT TSP-C52H8 | Cynomolgus | HEK293 | Cynomolgus TSLP Protein, His Tag (MALS verified) |  | | |
CEA-C074 | Human | - | Human TSLP ELISA Kit | |||
FRT-P012 | Human | - | Human TSLP / IL-7Rα & TSLP R Inhibitor Screening Kit (TR-FRET) | |||
TSP-H5253 | Human | HEK293 | Human TSLP Protein, Fc Tag, low endotoxin (MALS verified) |  | | |
TSP-H5254 | Human | HEK293 | Human TSLP (R127A, R130A) Protein, Fc Tag, low endotoxin (MALS verified) |  | | |
Total: 19
- 1
- 2
TSLP Background
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.
TSLP Synonyms
TSLP
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| QL-2302 | QL2302; QL-2302 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma | Details |
| GB-0895 | GB-0895 | Phase 3 Clinical | Generate Biomedicines Inc | Asthma; Immune System Diseases; Pulmonary Disease, Chronic Obstructive | Details |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| Lunsekimig | SAR-443765 | Phase 3 Clinical | Sanofi | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive | Details |
| Bosakitug | TQC-2731; BSI-045B; TQC2731; ATI-045 | Phase 3 Clinical | Biosion Inc | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| SHR-1905 | SHR-1905; AIO-001; GSK-5784283 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis | Details |
| CM-326 | CM-326 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| QX-008N | QX-008N; QX008N; JKN-2401; JKN2401; SNCA008; SNCA-008 | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| Solrikitug | NSI-8226; MK-8226 | Phase 2 Clinical | Merck & Co Inc | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Hypertension; Pulmonary Disease, Chronic Obstructive | Details |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| HBM-9378 | HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378 | Phase 2 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| CM-512 | CM512; CM-512 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis | Details |
| IBI-3002 | IBI3002; IBI-3002 | Phase 2 Clinical | Asthma; Dermatitis, Atopic | Details | |
| MG-ZG122 | MG-ZG122; MGZG122 | Phase 2 Clinical | Shanghai Mabgeek Biotechnology Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Amgen Inc, Astrazeneca Plc | Asthma | Details |
| TAVO-101 | TAVO-101; TAVO101 | Phase 2 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Dermatitis, Atopic; Hypersensitivity | Details |
| PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
| APG273 | APG273; APG-273 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| HBM-7575 | HBM-7575; SKB575; SKB-575; HBM7575 | Phase 1 Clinical | Harbour Biomed | Dermatitis, Atopic; Inflammation | Details |
| WIN-027 | QX027N; QX-027-N; WIN027; WIN-027 | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Dermatitis, Atopic | Details |
| HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive | Details |
| APG-333 | APG333; APG-333; PR018; PR-018 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma | Details |
| SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| BSI-502 | BSI-502; ATI-052 | Phase 1 Clinical | Biosion Inc | Autoimmune Diseases of the Nervous System; Inflammation | Details |
| CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Asthma; Fibrosis; Hypersensitivity; Inflammation | Details |
| STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthma | Details |
| LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
| GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Nasal Polyps; Sinusitis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | MEDI-9929; AMG-157 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Anaphylaxis; Asthma; Bronchial Diseases; Carcinoma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilic Esophagitis; Granulomatosis with Polyangiitis; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Lung Diseases; Lung Diseases, Obstructive; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Respiratory Tract Diseases; Sinusitis | Details |
Product Reviews
S***n2023-06-10
2People LikeWe got the TSLP recombinant protein from your company. The plan was to stimulate cell in vitro to see if it can induce a TH2 response. Your company offers the most cost effective option for the TSLP protein and with good customer service and express shipping. So far we do see some level of responses in the cells, we will perform more testing to validate the effects. The quality of the protein seems quite good and worth trying.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호